Wyeth

Janssen Sciences Ireland Uc

Janssen Alzheimer Immunotherapy

Prothena Biosciences Limited

Michael Grundman

James Callaway

Ivan Lieberburg

Lioudmila Tchistiakova

Davinder Gill

Angela Widom

Jack Steven Jacobsen

Lars Ekman

Keith M Gregg

Ronald Black

Wagner Marcelo Zago

Patrick Garidel

Andreas Langer

Manuel J Buttini

Gene G Kinney

Jim Callaway

The invention provides antibody formulations and methods useful for prophylaxis or treatment of synucleinopathies, including Parkinson's disease.

Antibody formulations and methods

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.

Immunotherapy regimes dependent on ApoE status

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Use of tau to monitor immunotherapy

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A&#x3b2;. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.

Treatment of amyloidogenic diseases

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A&#x3b2;. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.

Growing community of inventors

San Diego, CA, United States of America

Michael Grundman